-
Study aim
-
The effectiveness of oral colchicine and placebo on the need for urethral dilation after internal urethrotomy
-
Design
-
Totally, 176 patients with narrowing of the urethra candid for internal urethrotomy were chosen from the Ghaem Hospital, Mashhad, Iran. In this triple-blind, controlled clinical trial, the patients are assigned into parallel groups using simple and successive sampling methods.
-
Settings and conduct
-
Patients with narrowing of the urethra candid for internal urethrotomy who are candidates for internal urethrotomy at the Ghaem Hospital, Mashhad, Iran, are chosen. In this triple-blind study, sealed opaque envelopes will be used to conceal the sequencing. The participants, person responsible for data collection, and clinical care provider are blind to group allocation and the type of drugs.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: narrowing shorter than 1 centimeter in bulbar urethral stricture; single urethral strictures; first-time visitor; age over 20 years.
Exclusion criteria: sensitivity to colchicine; having gastrointestinal problems; the history of liver failure; the history of renal disease.
-
Intervention groups
-
The intervention group will receive 1 mg oral colchicine after internal urethrotomy for 6 weeks.
The control group will receive 1 mg oral placebo (Placebo will be produced the same of colchicine in terms of shape, size, taste, color, and odor by pharmaceutical company) after internal urethrotomy for 6 weeks.
-
Main outcome variables
-
Evaluation and comparison of the rate of urethral stricture, symptoms of acute urinary, and the rate of pain 6 weeks and 3 months after intervention in control and intervention groups.